February 5, 2013

Division of Dockets Management (HFA-305)
Food and Drug Administration
5630 Fishers Lane
Room 1061
Rockville, MD 20852

Docket Number: FDA-2012-N-1172

Dear FDA Officers:

The American Academy of Pain Medicine (AAPM), representing the specialty of pain medicine, writes to offer its guidance in considering the scientific evidence on the use of opioid drugs in the treatment of chronic pain. Our statement reflects the ongoing commitment of AAPM to curb prescription pain medication harm, including risks for addiction, misuse, and overdose death as well as inadequate access to treatment among patients with debilitating pain for whom opioid therapy is indicated.

The FDA has posed a number of questions regarding appropriate use of opioids in various populations with pain with a particular emphasis on evidence showing safety and efficacy and on the propriety of recent proposals to change drug dosage and duration controls. Respectfully, we ask that the FDA consider the following points.

First, the agency has requested clarification as to the definitions, diagnostic methods, and clinical implications pertaining to “mild,” “moderate,” and “severe” pain. As chronic opioid therapy is not recommended for mild pain, we will address our comments to the categories of moderate vs. severe pain. AAPM believes there is no clinical method to differentiate moderate from severe pain other than patient report. Also, there is often substantial variance over minutes, hours, and days in pain intensity reports; pain is not a static condition. Nor is there any scientific evidence to show that moderate pain has any more or less adverse outcomes than the labeling of pain as “severe.” Further, for years clinical trials leading to the approval of many of the currently available opioid formulations have used “moderate-to-severe pain” as the criterion in opioid efficacy studies, not severe pain only. For these reasons, AAPM affirms the position that limiting ongoing opioid therapy to patients who demonstrate severe pain would be clinically meaningless and lacking in a substantive scientific foundation.
Second, the agency requests information on the feasibility and possible clinical impacts of a labeling restriction that would set a maximum daily dose (e.g., 100 mg of morphine equivalents). Arbitrary dose limits disregard pharmacokinetic, pharmacodynamics, and pharmacogenetic differences among patients and inter-individual variability in opioid response and analgesia. As well, setting a ceiling dose such as 100 mg could be dangerously misleading, implying that doses below 100 mg are inherently safer than higher doses in any given individual or population of patients.

It is certainly likely that there is an overall correlation between dose and morbidity. However, this correlation is not a simple one, with several likely confounding variables, including medical and psychiatric co-morbidities and drug-drug interactions, among other factors. Elements of clinical assessment, dose titration, monitoring, and structured follow-up cannot be managed by designating an arbitrary dose ceiling. Rather, appropriate dosing requires education, training, and experience consistent with the larger sphere of complex chronic disease management. It is our respectfully stated view that to seek a simple solution to a complex problem would misdirect the more appropriate course of action that is needed to rectify gaps in prescriber capacity to prescribe safely.

Additionally, to fix on dose ignores other important factors known to be associated with unintentional overdose deaths. Initiating and/or rotating to methadone and other long-acting/extended-release opioids present key principles of prescribing not recognized in ceiling limits [Webster & Fine 2012:562-70; Webster & Fine 2012:571-4]. The Centers for Disease Control and Prevention (CDC) report that a third of opioid-related overdose deaths involve methadone (CDC 2012). We propose that if every prescriber knew how to safely prescribe methadone, we could rapidly reverse the incidence of prescription opioid deaths. Similarly, there is substantial evidence that benzodiazepines, and perhaps co-administration of other central-nervous system depressants, are major contributors to the deaths associated with opioids [Warner et al 2009]. A failure to address this evidence may lead to a false sense that dose is the issue, not the problematic interactions of various drugs throughout a range of doses.

Epidemiological studies showing that higher doses contribute to more deaths have been presented to support a restrictive ceiling dose [Dunn et al 2010; Bohnert et al 2011; Gomes et al 2011]. Close examination of these studies fails to show evidence that dose alone was the reason for overdose deaths. In one of the cited studies, Bohnert et al 2011, investigators retrospectively studied the Veterans Health Administration (VHA) database and reported that the rate of fatal overdose among patients treated with opioids was 0.04% with a higher risk among patients prescribed doses of ≥100 mg per day compared with those prescribed 1 to <20 mg per day. In Gomes et al 2011, a study of Canadians on public assistance, doses of >200 mg morphine equivalent per day were associated with nearly three times the risk of opioid-related mortality compared with doses of <20 mg [Gomes et al 2011].
These reports contain a high number of confounding factors that include a high prevalence of benzodiazepine involvement in fatalities in the Gomes study and a heterogeneous population with many comorbid psychiatric and substance-use disorders in the Bohnert study [Leavitt April 7, 2011]. In criticizing the “data mining” approach used by investigators, Leavitt wrote, “It also is curious in the [Bohnert] study that the greatest absolute number of overdose deaths (43.5%) occurred when the maximum prescribed daily opioid dose was listed as 0 mg/day. The authors had little explanation for this, other than many patients might have obtained opioids from non-VHA healthcare providers, and some might have saved opioids from a prior prescription or obtained them from illicit sources [Leavitt April 7, 2011].”

Furthermore, the studies failed to analyze methadone as a medication shown by the CDC to contribute to a disproportionate number of overdose deaths when compared to the quantity of methadone prescriptions [CDC 2012]. Both studies specifically excluded methadone from analysis, explaining that methadone equates poorly to morphine equivalents and that it is used more frequently (in Canada, the setting of the Gomes study) for addiction treatment than pain.

Importantly, there is no comparative data presented on the risk or incidence of suicide resulting from inadequate pain control, recognizing that this risk in patients with chronic pain is double the control population rate [Tang & Crane 2006]. We infer that it is premature to conclude that an arbitrary dose limitation in opioid labeling will beneficially reduce mortality, but there is good cause for concern that such a maneuver, well intended as it may be, could have serious unintended consequences, including inciting morbidity and mortality among chronic pain sufferers due to uncontrolled pain. This remains an important area for much needed research and professional education.

Proponents of dose restrictions also cite evidence that high doses of opioids are associated with increased risk of overdose death, emergency room visits, and fractures in the elderly [Miller et al 2011]. Indeed, higher doses of opioids are associated with increased risk of harm in a subset of the pain population; however, as we have cited above, dose is only one contributing factor. The research results reported on by Miller and colleagues show propoxyphene was the opioid most commonly prescribed. This opioid is not considered highly potent and is no longer on the market. In addition the study has been aptly criticized for serious flaws in the analysis of the data [Widera 2011]. On balance, great caution should be exercised in interpreting conclusions. We advocate opioids generally be limited to patients who have failed other safer and more effective therapies. But specifically, physicians involved in the care of older individuals need to understand the unique aspects of geriatrics and pharmacotherapy, and through this understanding provide informed, salutary treatment options, monitoring appropriately to prevent adverse events. This is a population at risk for falls and fractures, including as a result of under-treated pain. The compact between physician and patient (or proxy) should determine how best to strike the optimal balance in ascertaining treatment decisions. When an approved drug is deemed appropriate based
upon a patient’s specific circumstances and in the absence of any contraindications, the treating physician must have the latitude to determine what serves the best interest of her patient. This is the essence of the practice of medicine.

Third, the maximum duration for continuous (daily) use of opioids for noncancer pain has been called into question with a specific proposal to revise the label by limiting such use to 90 days. Pointedly stated, such a change would effectively eliminate the use of opioids for chronic noncancer pain. This is a radical position that would leave an untold number of pain sufferers with few treatment options given the on-label restrictions imposed by many insurers, including Medicare/Medicaid. The Washington Legal Foundation, a non-profit organization based in Washington, D.C., recently published a paper predicting an exodus of physicians from the pain-management specialty and a disproportionate negative impact on poorer citizens who need pain care as a result of new stricter opioid regulations in Washington State. The following paragraph is a quote from that paper:

“Washington Department of Health officials, recognizing that opioid therapy will become increasingly difficult to obtain, proposed that chronic pain patients should explore alternative treatments for relieving pain, such as ‘physical therapy, yoga, massages or acupuncture.’ Unfortunately (and ironically), a majority of these alternative medicine options are not covered under Washington’s Medicaid program because they are not clinically proven, rendering these ‘choices’ financially unrealistic for many patients who suffer from chronic pain [Meringola 2011].”

Further, the Foundation averred that that the regulations impose a strong prejudicial bias, since they aim to deter opioid-related harm by targeting those with chronic noncancer pain, while ignoring problematic consequences of opioid prescribing in acute care venues, emergency departments, surgical settings, cancer pain treatment centers, and in palliative care.

While we believe that there is a need to balance risks to patients with pain vs. potential harms to the general public, we construe a 90-day labeling limit on duration of prescribing to weigh excessively against the target population (patients with moderate-to-severe chronic debilitating pain) for whom the currently approved long-acting opioid analgesics are indicated. This consequence is predictable insofar as prescribers will seek safe harbor for prescribing within dose and duration limits, because labeling has become the *de facto* standard of care, defining “legitimate practice.” The highly interpretable language of the Controlled Substances Act, which speaks of “legitimate medical purpose,” creates additional risk for prescribers if they deviate from language within the labeling. Therefore, even though neither the FDA nor the DEA regulate the practice of medicine, in this particular sphere, they powerfully and pointedly affect the practice of medicine.
We conclude that promoting the view that lower doses or durations of treatment are protective could provide a false sense of security for patients and practitioners. Danger lies in failing to address the more salient issue of prescriber education and adherence to principles of practice, including ongoing monitoring for aberrant behaviors and early signs of addiction.

Fourth, the agency requests input on the potential for regulatory changes to reduce abuse and misuse of opioids. We acknowledge the problem with opioid-related harm and agree that more must be done to reverse these problems. However, there are two separate populations that need different solutions: the population of patients treated with opioids for pain and the population of nonmedical users of opioids. Evidence from the National Survey on Drug Use and Health suggests that more than two-thirds of nonmedical users get opioids from family or friends [SAMHSA 2010]. Much of society’s problem with nonmedical use is due to leftover medication stemming from the prescribing of more opioids than necessary for acute and trauma pain, not chronic noncancer pain [Bates 2011, SAMHSA 2010]. It would be an error to try to solve the problem of nonmedical use by denying people with pain access to medication.

Furthermore, research seeking to establish prevalence of addiction in chronic noncancer pain patients who receive chronic opioid therapy suffers from a lack of standardized criteria for establishing addiction. We suggest that interpretation of data depends on the definitions researchers used for aberrant behaviors, misuse, use, addiction, and related terms. We further affirm that these terms are not equivalent in clinical implications. Consider, for example, recent surveys that used DSM criteria and found high rates of addiction in chronic noncancer pain patients receiving chronic opioid therapy. Boscario et al 2011 compared diagnostic criteria for opioid dependence contained in the fourth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) with those in the updated DSM-V for an opioid-use disorder. This analysis was accomplished by combining the prior categories “abuse” and “dependence” into a single opioid-use disorder category and then grading the severity. This move away from indistinct categories, such as “abuse,” might be beneficial, reflecting the evolution of neuroscience and an empirically-based understanding of the relationships among a given chemical, an individual’s genetic and environmental circumstances, and the disease of addiction. However, many of the criteria investigators used to identify opioid-use disorders resemble common behaviors of patients with uncontrolled pain (e.g., taking more than intended, unsuccessful attempts to cut down intake), casting doubt on the reported signs of “addiction.” Each of the criteria in the DSM-V could result from an entirely different cause or motivation when observed in patients with pain than in nonmedical users seeking the same drugs. If the study is interpreted to say 35% of patients may have trouble managing opioid intake, it is consistent with prior studies assessing problematic opioid use behaviors (and some of these behaviors can be managed with structured approaches to care and appropriate monitoring). But it is false to conclude that this number equates with the prevalence of “addiction,” or that addiction is an inevitable consequence of chronic opioid therapy in...
patients without predisposing factors. This distinction is of great importance, because it implies very different approaches to care in distinct populations of patients (based upon risk assessment) and prognoses.

Such problems with terminology may contribute to conflicting views of research findings. Fleming and colleagues conducted two-hour interviews with 801 patients receiving long-term opioid therapy who were being treated by 235 Wisconsin physicians. An analysis of this study by Von Korff and colleagues emphasized the following findings: “They found rates of 26% for purposeful oversedation, 39% for increasing dose without prescription, 8% for obtaining extra opioids from other doctors, 18% for use for purposes other than pain, 20% for drinking alcohol to relieve pain, and 12% for hoarding pain medications [Von Korff 2011].” The sum of these aberrant behaviors is troublesome. Yet Fleming et al has also frequently been cited as showing that opioid-use disorders — a term usually equated with “addiction” — were 3.8% in the sample studied [Fleming 2007]. For patients who are able to sustain long-term benefit from opioid therapy, the risk of addiction appears low in some studies. In a review of 26 studies (total enrollment of participants: 4,893) that reported data after six months of chronic pain treatment with opioids, signs of iatrogenic addiction were reported in 0.27% of participants [Noble et al 2010]. Such results suggest that chronic opioids cannot be assumed to be the wrong treatment for all patients at the start.

Some evidence shows that patients with mental-health comorbidities are more likely to receive chronic opioid therapy than patients who lack these risk factors [Braden et al 2009], a phenomenon referred to as adverse selection. However, people with pain and mental-health disorders also deserve to have their pain treated. This is an increased risk population that requires vigilance and more medical involvement, not less. It is acknowledged that this population is more difficult to treat largely because it is hard to know when the drug is being used for pain or for the mental disorder or both. Some of these patients need strict monitoring, and some should not receive long-term opioids. This is where we need more research and medical training, but it is not a reason to deny people with pain an opioid if it is appropriate.

Marketing efforts by industries that manufacture and distribute opioids have been accused of minimizing opioid risks and exaggerating benefits, thus contributing to harm in patients and the general public. AAPM believes the marketing issue needs ongoing vigilance, but making medications more difficult to obtain by people who benefit from them will not address the marketing issue. A clear distinction must be made between the important public health campaign (intended to increase awareness of the adverse consequences of under-treated chronic pain and the critical elements of assessment and optimal management) vs. the marketing and promotion of opioids by pharmaceutical companies. To conflate these issues leads to specious conclusions and solutions, essentially “throwing the baby out with the bathwater.” We suggest that there are better means to the mutually agreed-upon salutary ends of safe and effective use.
Fifth, the long-term safety and effectiveness of managing chronic noncancer pain with opioids has been questioned. Indeed, little research reaching highest standards of scientific rigor has focused on the question of long-term effectiveness of opioid therapy for chronic noncancer pain. The majority of recommendations from a practice guideline endorsed by the American Pain Society and the American Academy of Pain Medicine are based on lower-quality evidence [Chou et al 2009]. At best, the literature has shown inconsistent effectiveness of opioids for chronic pain [Trescot 2008].

A systematic review of patients with chronic back pain by Martell et al found opioids relieved pain for up to 16 weeks but that long-term benefit was uncertain; furthermore, patients exhibited a high incidence of substance-use disorders [Martell 2007]. However, co-morbid conditions are frequent with chronic back pain, including major depression in 18% to 32% of patients [Ballantyne 2007]. Therefore, it may be unwise to use these patients as a yardstick by which to measure the likelihood of success with opioids in all patients. Some evidence suggests that patients with depression, regardless of pain condition, do not respond as well to opioid therapy as non-depressed patients [Middleton & Pollard 2005]. Perhaps it is patients without co-morbid disorders who achieve the most benefit from opioid therapy. Therefore, screening of patients for mental-health and substance-use co-morbidities may be the most important step in assuring proper candidate selection for long-term opioid therapy.

Regardless, it is clear from clinical experience and the literature that there are many patients who do benefit. Even though opioid trials are plagued by high dropout rates due to adverse effects or ineffective analgesia, a subset of patients continues to achieve meaningful pain control long term [Noble et al 2010]. In patients who had been taking opioids for chronic pain for an average of two years, when the treatment was suddenly stopped, the patients experienced more pain and a reduced quality of life – not an uncontrolled craving for drugs [Cowan et al 2005]. Furthermore, the degree of pain relief that is meaningful to the patient must be taken into consideration. If patients do not achieve effective pain relief with one opioid, rotation to another frequently produces greater success [Quang-Cantagrel 2000]. For many of these patients, other treatments have failed and restrictions on the availability of opioids within a full potentially therapeutic range sentence them to suffer needlessly. In the absence of highly sensitive and specific predictive factors, clinicians must rely on well-defined risk mitigation practices that have emerged in order to create the most propitious benefit-to-harm ratio for each patient under treatment. This cannot be adjudicated through a priori constrained dose and duration parameters.

Finally, we would like to address certain misconceptions in the characterization of chronic pain. Some have argued that the very fact that some patients remain on opioids for extended periods justify a need for more restrictions regarding dose and duration. For instance, a large sample of medical and pharmacy claims records showed that two-thirds of patients who took opioids on a daily basis for 90 days were still taking opioids five years later. However, it is unclear how this finding differs from patients on insulin,
statins, antihypertensives, etc. Chronic pain is in most cases just that, a chronic disorder that may be life long, often due to damage sustained to tissues or the nervous system. AAPM would not support arbitrary limits on dose or duration for the specific treatment of any chronic condition in patients who are using their prescribed medication safely and effectively (i.e., meeting defined goals of treatment), regardless of the chronic condition, including chronic pain.

It is true that many chronic noncancer pain patients receiving chronic opioid therapy continue to experience significant chronic pain and dysfunction. The same could be stated about the plight of most patients with chronic progressive conditions treated with well-accepted therapies, including those with COPD, heart failure, or neurodegenerative diseases, among many others. For patients living with chronic pain, the goal of opioid therapy is not to eliminate all pain – which is currently impossible in most instances – but to help improve and restore function and optimize quality of life to the greatest extent possible. Expecting any treatment, including opioids, to eliminate intractable pain is unrealistic, as much so as expecting miraculous recovery of muscle control in multiple sclerosis patients given the limitations of current treatments.

AAPM shares the concern about the need to find ways to curb harm when prescription pain medications are misused and when barriers are erected to access for patients. Increased funding for research and patient and prescriber education will go a long way toward meeting the goal of ensuring patient safety within the parameters of therapeutic treatment options. We welcome the opportunity to participate in a dialogue with FDA and other interested parties, including prescribers, pharmacists, behavioral health practitioners, other healthcare professionals, the scientific community, government agencies, and patients, in reaching a positive outcome for those Americans who suffer unnecessarily with chronic pain.

Sincerely,

Martin Grabois, MD
President

Additional signatures on separate page
References


Acknowledgment: Technical writing assistance provided by Dove Medical Communications, LLC, Salt Lake City, Utah (dove.beth@gmail.com).